Abstract
L-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the L-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases. [Abstract copyright: © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.]
| Original language | English |
|---|---|
| Pages (from-to) | 150 |
| Journal | Medical oncology (Northwood, London, England) |
| Volume | 40 |
| Issue number | 5 |
| Early online date | 15 Apr 2023 |
| DOIs | |
| Publication status | E-pub ahead of print - 15 Apr 2023 |
Keywords
- Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
- Asparaginase - therapeutic use - adverse effects
- Drug-Related Side Effects and Adverse Reactions
- Immunogenicity
- Acute lymphoblastic leukemia
- Hypersensitivity
- Asparaginase
- Drug Hypersensitivity
- Humans
- Child
- Antineoplastic Agents - adverse effects
- Antineoplastic agent